Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Scripps Research team creates new synthetic compound with HIV-fighting promise

19.01.2011
Discovery stems from library created using natural Japanese-plant compounds as starting point

Using chemical compounds found in a Japanese plant as a lead and the clever application of ultraviolet light, a Scripps Research Institute team has created a unique library of dozens of synthetic compounds to test for biomedical potential. Already, one of the compounds has shown great promise in inhibiting replication of HIV particles and fighting inflammation.

With the report of their work scheduled to appear in the online Early Edition of Proceedings of the National Academy of Sciences this week, the researchers now plan to optimize the compound's pharmaceutical potential so that it can be pursued as a drug candidate.

The plant Hypericum chinense, known in Japan as biyouyanagi, produces beautiful yellow flowers and, as it happens, potent chemical compounds known as biyouyanagins that have already shown promising anti-HIV and anti-tumor activity. That got the attention of K.C. Nicolaou, who holds the titles chair of the Department of Chemistry, Aline W. and L.S. Skaggs Professor of Chemical Biology, and Darlene Shiley Chair in Chemistry at Scripps Research. Nicolaou's interest was also piqued because the plant is from the same family that produces St. John's wort, and the biyouyanagins possess an intriguing molecular architecture.

"It was the perfect recipe for convincing a synthetic chemist to get into the game," said Nicolaou, who spearheaded the project in collaboration with a number of Scripps Research colleagues. "It seemed like there was so much to be discovered."

Best of Both Worlds

Within the biomedical field there are some researchers that argue natural products are the best route to new drug discovery. Others laud the potential of designing completely synthetic drugs. "I belong to both camps," says Nicolaou, because he prefers to start with natural products and then modify them in a variety of ways to create new synthetic products with improved potential. "The power of this method is that it allows us to build on the natural structures to make a whole new and diverse family of compounds."

An unexpected side result of the group's initial work was the discovery that the structure previously reported for the biyouyanagins was slightly off. With the proper structures in hand, the Nicolaou team recognized it could induce formation of critical bonds that join the two domains of the molecules by bombarding the right chemical building blocks with ultraviolet light.

This technique, known as photocycloaddition, allowed the scientists to synthesize the two known biyouyanagins as well as a third type not yet discovered in nature. The scientists then began combining a variety of different building blocks—some commercially available and others they produced in the lab—using the photocycloaddition to build a library of about 50 analogs, compounds similar to the originals but with significant chemical variations.

The resulting compounds then went in groups to various collaborating Scripps Research laboratories. Professor Dennis Burton's lab analyzed the compounds' ability to inhibit replication of HIV. Chair of the Department of Chemical Physiology Ben Cravatt's team looked at anti-inflammatory potential. Professor Juan de la Torre's group examined effects against LCMV, the prototype member of the arenavirus family that includes several causative agents of deadly hemorrhagic fever disease in West Africa and South America.

All of the compounds in the team's new library are, like aspirin, considered small molecules. Nicolaou believes these offer the best biomedical potential. Larger molecules such as proteins are finding new medical applications, but have to be injected and are often short-lived and very expensive.

"If you can discover small molecules that work, they're affordable and they last long enough in the body to do their jobs," he said. "Those are the magic bullets."

A Promising Lead

One compound from the new library, number 53, stood out. One side of its structure is essentially the same as that of a natural biyouyanagin, while the other side is a departure comprising a structural motif like the bases found in DNA. In the HIV testing, it compared favorably with the well-known AIDS drug AZT, though it is not yet as potent. In the anti-inflammatory tests, it was as potent or more so than commercially available products. This particular compound hasn't been tested for its potential against arenaviruses, but Nicolaou is hopeful the team will eventually find interesting activity there as well.

"We were certainly excited to see those results," says Nicolaou. "It's quite a promising lead." Next, the team will tinker with 53's initial structure in search of modifications that will increase its potency. Once its biomedical activities are optimized, the group will consider pushing the compound toward the drug-testing process.

This work was funded by the National Institutes of Health, the Skaggs Institute for Chemical Biology, the Universita degli Studi di Urbino "Carlo Bo", the Japanese Society for the Promotion of Science, the Natural Sciences and Engineering Research Council of Canada, and the National Institute on Drug Abuse.

In addition to Nicolaou, Burton, Cravatt, and de la Torre, authors of the paper, titled "Design, synthesis, and biological evaluation of a biyouyanagin compound library," were Silvano Sanchini, David Sarlah, Gang Lu, T. Robert Wu, Daniel Nomura, Beatrice Cubitt, and Ann Hessell, all from The Scripps Research Institute.

About The Scripps Research Institute

The Scripps Research Institute is one of the world's largest independent, non-profit biomedical research organizations, at the forefront of basic biomedical science that seeks to comprehend the most fundamental processes of life. Scripps Research is internationally recognized for its discoveries in immunology, molecular and cellular biology, chemistry, neurosciences, autoimmune, cardiovascular, and infectious diseases, and synthetic vaccine development. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, Scripps Research currently employs approximately 3,000 scientists, postdoctoral fellows, scientific and other technicians, doctoral degree graduate students, and administrative and technical support personnel. Headquartered in La Jolla, California, the institute also includes Scripps Florida, whose researchers focus on basic biomedical science, drug discovery, and technology development. Scripps Florida is located in Jupiter, Florida. For more information, see www.scripps.edu .

Mika Ono | EurekAlert!
Further information:
http://www.scripps.edu

More articles from Life Sciences:

nachricht Modern genetic sequencing tools give clearer picture of how corals are related
17.08.2017 | University of Washington

nachricht The irresistible fragrance of dying vinegar flies
16.08.2017 | Max-Planck-Institut für chemische Ökologie

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

Gold shines through properties of nano biosensors

17.08.2017 | Physics and Astronomy

Greenland ice flow likely to speed up: New data assert glaciers move over sediment, which gets more slippery as it gets wetter

17.08.2017 | Earth Sciences

Mars 2020 mission to use smart methods to seek signs of past life

17.08.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>